Hisamitsu Pharmaceutical Co (TSE:4530) NonCurrent Deferred Liabilities: 円0 Mil (As of Nov. 2025)


TSE:4530 Hisamitsu Pharmaceutical Co Inc TSE:4530
69 GF Score
Price 円6,040.00
GF Value 円4,918.72
Valuation Modestly Overvalued
View Full Analysis

What is Hisamitsu Pharmaceutical Co NonCurrent Deferred Liabilities?

Hisamitsu Pharmaceutical Co TSE:4530 69 NonCurrent Deferred Liabilities is 円0 Mil as of Nov. 2025. GuruFocus rates TSE:4530 with a GF Score™ of 69/100 and a GF Value™ of 円4,918.72 (Modestly Overvalued).

Non-Current Deferred Liabilities represents the non-current portion of obligations, which is a liability that usually would have been paid but is now pas due.

Hisamitsu Pharmaceutical Co's non-current deferred liabilities for the quarter that ended in Nov. 2025 was 円0 Mil.

Hisamitsu Pharmaceutical Co NonCurrent Deferred Liabilities Related Terms

Hisamitsu Pharmaceutical Co NonCurrent Deferred Liabilities Historical Data

* Premium members only.

The historical data trend for Hisamitsu Pharmaceutical Co's NonCurrent Deferred Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Hisamitsu Pharmaceutical Co NonCurrent Deferred Liabilities Chart

Hisamitsu Pharmaceutical Co Annual Data
Trend Feb17 Feb18 Feb19 Feb20 Feb21 Feb22 Feb23 Feb24 Feb25 Feb26
NonCurrent Deferred Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Hisamitsu Pharmaceutical Co Quarterly Data
May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24 Feb25 May25 Aug25 Nov25 Feb26
NonCurrent Deferred Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
TSE:4530
69GF Score
Hisamitsu Pharmaceutical Co Inc TSE:4530
NonCurrent Deferred Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a NonCurrent Deferred Liabilities of 円0 Mil mean?
Hisamitsu Pharmaceutical Co (TSE:4530) has a NonCurrent Deferred Liabilities of 円0 Mil as of Nov. 2025. Non-current deferred liabilities represent the company obligations not paid yet not due within the current period. View historical data on Hisamitsu Pharmaceutical Co and its competitors.
Is Hisamitsu Pharmaceutical Co's NonCurrent Deferred Liabilities too high?
Hisamitsu Pharmaceutical Co's current NonCurrent Deferred Liabilities is 円0 Mil. Overall, Hisamitsu Pharmaceutical Co has a GF Score™ of 69/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Hisamitsu Pharmaceutical Co's NonCurrent Deferred Liabilities compare to ESPR and AMPH?
Hisamitsu Pharmaceutical Co's NonCurrent Deferred Liabilities of 円0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good NonCurrent Deferred Liabilities for a Drug Manufacturers company?
A good NonCurrent Deferred Liabilities depends on the Drug Manufacturers industry context. However, NonCurrent Deferred Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high NonCurrent Deferred Liabilities mean?
A high NonCurrent Deferred Liabilities can signal that a stock is expensive relative to its fundamentals. Non-current deferred liabilities represent the company obligations not paid yet not due within the current period. View historical data on Hisamitsu Pharmaceutical Co and its competitors. Hisamitsu Pharmaceutical Co's current NonCurrent Deferred Liabilities is 円0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hisamitsu Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Hisamitsu Pharmaceutical Co (TSE:4530) is currently considered Modestly Overvalued. The stock's GF Value™ is 円4,918.72, compared to a current price of 円6,040.00 — trading 22.8% above its estimated fair value. The current NonCurrent Deferred Liabilities is 円0 Mil. Hisamitsu Pharmaceutical Co's overall GF Score™ is 69/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is NonCurrent Deferred Liabilities calculated?
NonCurrent Deferred Liabilities is calculated from a company's financial statements. For Hisamitsu Pharmaceutical Co (TSE:4530), the current NonCurrent Deferred Liabilities is 円0 Mil as of Nov. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Hisamitsu Pharmaceutical Co (TSE:4530) Overvalued in 2026?

Based on GuruFocus' analysis, Hisamitsu Pharmaceutical Co stock appears to be overvalued. The current stock price of 円6,040.00 is trading 22.8% above its estimated GF Value™ of 円4,918.72. GuruFocus considers Hisamitsu Pharmaceutical Co to be Modestly Overvalued.

Key valuation signals for TSE:4530:

  • NonCurrent Deferred Liabilities: 円0 Mil
  • GF Value™: 円4,918.72 vs. price of 円6,040.00 (22.8% above fair value)
  • GF Score™: 69/100

No single metric tells the full story. See the TSE:4530 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Hisamitsu Pharmaceutical Co Business Description

Other Exchanges HTSUY:USA
Address 408 Tashiro Daikancho, Saga Prefecture, Tosu, JPN, 841-0017
Hisamitsu Pharmaceutical Co Inc is engaged in the research, development, manufacturing, procurement, and sale of pharmaceutical products. The company operates a single business segment, focusing on medical and general pharmaceuticals both in Japan and overseas. It markets drugs under the Salonpas, Nobinobi / Salonsip, Butenalock, and Mohrus brands, which mainly serve topical medication needs with pain relief creams, gels, sprays, lotions, and ointments.
69GF Score

Get the complete analysis for TSE:4530

NonCurrent Deferred Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円6,040.00
Price
円4,918.72
GF Value